Search results for "Blood" in Articles / App Notes
Article
Taking a “Development-by-Design” Approach to Cell Therapies
has been partnering with CMDG LLC on cord blood processing technology. Following are some of the equipment manufacturers and systems applied in cell therapy development and manufacturing:
Beckman …
Article
A Bright Future for the Plasma Fractionation Industry
There is a strong demand for plasma products in China, especially considering that ever since 1985 China has banned importation of almost all blood products, due to the concern for HIV epidemic. There…
Article
Continuous Manufacturing: A Changing Processing Paradigm
…d out the first end-to-end, completely continuous synthesis and formulation of a treatment for high blood pressure in 2013, aliskiren hemifumarate (16). While this drug is not a biologic, Bernhardt L…
Article
FDA Approves First Biosimilar
…rapy, with cancer undergoing bone marrow transplantation, for those receiving autologous peripheral blood progenitor call collection and therapy, and for patients with neutropenia. The approval trail…
Article
Improving PAT for Biologics
Siemens is also exploring synergies with the analytical techniques applied for the healthcare sector, such as blood gas analyzers, to biologics production. “Sharing technologies looks quite promising …
Article
Setting Standards for Biotech Therapeutics in India
It also included monographs of biologically derived products such as vaccines, immunosera for human use, blood products, and other biotech and veterinary (biological and non-biological) preparations. …
Article
Trends in BioPharma Approvals in 2013
In 2013, 20 products containing new biopharmaceutical molecular entities (defined herein as recombinant proteins, monoclonal antibody or biosynthesized nucleic acid-based products) were approved in t…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
It is unlikely that blood or plasma-derived products or complex vaccines will be acceptable as biosimilars in the US or Europe due to their complexity (47). However, eight categories of biosimilar mol…